Psychedelic therapy is emerging as a transformative treatment model for mental health conditions, particularly treatment-resistant depression and PTSD. Unlike daily medications, psychedelic therapy is an interventional approach administered 1-6 times with durable long-term benefits. Companies like Compass Pathways are advancing FDA trials, while the real investment opportunity may lie in the $10,000-$20,000 treatment services rather than just the drugs themselves. Big Pharma remains cautiously interested but not yet aggressively pursuing the space.

Johnson & Johnson, a Dividend King with 64 consecutive years of dividend increases, is transforming into a growth company after streamlining operations. The company's stock has rallied over 50% in the past 12 months, driven by its focus on two core segments: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). Despite expected 15% EPS decline in 2026 due to Stelara patent loss, analysts project 11% EPS growth in 2027 and 7% in 2028 as the company launches new drugs and grows its core businesses.

Over 100 pharmaceutical companies are competing to develop 120+ pipeline drugs for non-small cell lung cancer (NSCLC), with approximately 30+ drugs in late-stage development. The competitive landscape is driven by precision oncology advances, including next-generation targeted agents and immunotherapy combinations. Recent FDA approvals and designations highlight innovation in treating EGFR-mutated, ALK-positive, and other biomarker-selected NSCLC populations.

The U.S. cardiovascular devices market is projected to nearly double from $22.08 billion in 2025 to $41.29 billion by 2032, driven by aging demographics and AI-powered clinical tools. Remote cardiac monitoring and minimally invasive surgery markets are expanding rapidly at 11.3% and 16.05% CAGRs respectively. Major industry players announced significant developments: GE HealthCare and Medtronic integrated surgical visualization systems, Intuitive Surgical received FDA clearance for da Vinci 5 cardiac procedures, and Johnson & Johnson presented mixed results from cardiac intervention trials.

MeiraGTx reacquired bota-vec, a treatment for X-linked retinitis pigmentosa (XLRP), from Johnson & Johnson for a $25 million upfront payment. The company raised $100 million through a share offering and plans to expedite regulatory filings for U.S. and EU approval with a potential 2027 launch. Three-year data from its xerostomia treatment showed durable benefits. Stock declined 15.8% on the announcement.

The global ambulatory surgical equipment market is valued at USD 7.39 billion in 2026 and is expected to reach USD 14.58 billion by 2035, growing at a 7.85% CAGR. North America dominates with 34% market share, while Asia Pacific is the fastest-growing region. Endoscopy and laparoscopy systems lead by product type at 18% share, with compact intraoperative imaging expected to grow fastest. Independent ambulatory surgical centers account for 42% of the market.

MeiraGTx has entered into an asset purchase agreement with Johnson & Johnson to acquire all interests in botaretigene sparoparvovec (bota-vec) for treating X-linked retinitis pigmentosa. The company will pay $25 million upfront plus regulatory and commercial milestones, with royalties on global net sales. Phase 3 LUMEOS study data showed clinically meaningful improvements across multiple vision domains, with 45% of treated patients gaining >10 letters in low luminance visual acuity. MeiraGTx intends to file for regulatory approval in the U.S., EU, and Japan with a potential launch in 2027.

Johnson & Johnson's Q1 earnings showed solid revenue growth of 9.9% and management raised guidance, though earnings per share declined 2.5% due to patent expirations and increased competition. Technical analysis suggests a Bull Flag formation with potential 20% upside to $290, supported by strong institutional ownership, positive analyst sentiment, and a robust pipeline expected to drive 5-7% annualized revenue growth.

Johnson & Johnson reported Q1 2025 adjusted earnings of $2.70 per share, beating consensus, with sales of $24.06 billion up 9.9% YoY. Cancer drug revenue surged 22.8%, driven by oncology and neuroscience products, while immunology sales declined. The company raised its FY2026 guidance and increased its dividend by 3.1% to $1.34 per share, marking 64 consecutive years of growth. However, free cash flow fell 55.6% YoY to $1.50 billion.

Mestag Therapeutics announced that its FAP-targeted LTBR agonist bispecific antibody MST-0312 has been selected for a late-breaking poster presentation at the AACR Annual Meeting in April 2026. The compound is designed to induce tertiary lymphoid structures for solid tumor treatment and is anticipated to enter clinical trials mid-2026 with the Phase 1 STARLYS trial.

Eli Lilly announced positive Phase 3 trial results for Jaypirca (pirtobrutinib), marking the fourth successful study for the blood cancer treatment. The BRUIN CLL-322 trial showed significant improvement in progression-free survival when combined with venetoclax and rituximab in patients with chronic lymphocytic leukemia. The company plans to submit results for label expansion later this year. Head-to-head data also demonstrated Jaypirca's competitive advantage over Johnson & Johnson's Imbruvica.

With S&P 500 dividend yields at historic lows of 1.2%, the article highlights three Dividend King stocks offering superior yields: AbbVie (3.20%), Procter & Gamble (2.91%), and Coca-Cola (2.66%). Despite AbbVie facing competition from a new rival drug, all three companies demonstrate strong cash generation, reliable dividend growth, and resilient business models that make them attractive for income investors.